r/valueinvesting
$ZTS (Zoetis): a 25% ROIC animal-health compounder that just halved. Value, or value trap?
ZTS fell 53% to $80 despite strong fundamentals. Author sees it undervalued (DCF $94) despite stalled growth and high debt.
- Exceptional fundamentals with 24.7% ROIC, 39% operating margins, and consistent share buybacks reducing float.
- Strong competitive moat in animal health driven by pet humanization, lack of insurance pressure, and high vet stickiness.
- Attractive valuation at 13x PE and 6.7% FCF yield, with conservative DCF indicating intrinsic value around $94.
- Growth has stalled with only 2% revenue growth and flat FCF as key products mature and competition emerges.
- Balance sheet carries a blemish with $7.3B net debt, roughly 3.3x free cash flow.
Zoetis is down about 53% over the past year, sitting near $80 against a 52 week high of $164. I had this company on my watchlist for a while, but it was always higher-prices. So a drop this brutal got my attention. The question I keep wrestling with is whether the market has handed me a gift or is trying to tell me something I should listen to.
If we look at the fundamental quality of Zoetis, it's exactly what I love
\- ROIC of 24.7% with operating margins around 39%, both still rising year on year
\- Share count down roughly 10% over the past few years on steady buybacks (470M down to 422M)
\- A dividend yielding 2.65% on just a 33% payout, 13 straight years of growth, almost 19% a year over the last five
\- Net income still grew 7.5% last year even with the top line stalling
And it sits in a really nice corner of the market. People treat their pets like family and they don't cut the vet bill when things get tight, there's no insurer squeezing prices like in human pharma, and vets get sticky once they trust a product. Zoetis is the clear leader across all of it.
So why has it cratered? A few reasons, and they're not nothing:
\- Growth has basically stalled. Revenue only grew about 2% last year and free cash flow was flat to slightly down. The Apoquel and Librela story that carried the stock for years is maturing, and competition in the pet pain market is finally showing up.
\- The balance sheet is the one real blemish. Net debt is around $7.3B, roughly 3.3x free cash flow. Not scary for cash flows this steady, but it's the single box on the scorecard that outright fails, and it's hard to unsee :/
On valuation, you're now paying 13x earnings, 15x free cash flow, under 10x EV to EBITDA, with a 6.7% free cash flow yield. For a business this good, that's cheap in absolute terms. But when I run a conservative DCF (around 5% FCF growth fading to a 2.5% terminal, 8% discount) I get an intrinsic value near $94 against the $80 price. So there's a real discount to fair value, just not the fat margin of safety I'd want before going all in.
Where I land, at least today: this feels like a wonderful business at a fair to slightly cheap price, the classic quality at a reasonable price setup rather than a deep value steal. The whole thing hinges on one question, whether the growth slowdown is a pause or the new normal, and I genuinely can't tell yet.
If you've followed Zoetis closely, is the revenue stall just a rough patch (tough comps, Librela still ramping) or something more structural? And does 3.3x net debt to FCF bother you for cash flows this durable? Trying to talk myself into or out of starting a position here.
Did you miss the lawsuits ZTS is getting hit with? There is a securities fraud class action against them right now. You always need to find the context behind everything and ZTS is cheap right now for serious, structural reasons.
“The balance sheet is the one real blemish”
This is where you lost me. That is not a good sentence to utter when investing.
What?
Warren Buffett’s classic quote about these stocks: “It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.”
True that!
Looking at the earnings growth right now, it doesn’t look massively undervalued.
The other issue I see is that management has not really seem to be aware what to do about all of this. For many quarters, they were just lying to investors about how good growth prospects were. And the opposite happened.
So either they’re oblivious about the outlook for their business (simply not in control of the available levers) or they simply can’t be trusted.
This feels like one of those cases where the market isn’t questioning the moat, it’s questioning the runway.
No Commercial Advertising - No posts or comments advertising commercial products or services (including newsletters, subscriptions, services, tools, websites, apps, etc.).
Free services may be introduced once. Do not violate the "No Spam" rule.
Self-promotion of articles you authored is allowed if on-topic, and linked articles (off-site) may contain ads or links to newsletters or services. Use modmail to ask the moderators first if you are unsure.
Ads on Reddit can be purchased at https://ads.reddit.com/
Inflexible demand doesn't necessarily mean inflexible price, with how much these industries are struggling due to interest rate, inflation and fuel prices, there genuinely isn't room to price gouge much further which is the main way companies like zoetis grow.